A phase 1 study to assess the mass balance, pharmacokinetics, metabolism, and excretion of GSBR-1290, containing a microtracer dose of [14C] GSBR-1290, in healthy participants

2024-512578-83-00 Protocol GSBR-1290-07 Human pharmacology (Phase I) - Other Ended

Start 24 Jun 2024 · End 9 Sep 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol GSBR-1290-07

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 8
Countries 1
Sites 1

Not applicable - Healthy volonteers

Key facts

Sponsor
Structure Therapeutics Inc.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hormonal diseases [C19]
Trial duration
24 Jun 2024 → 9 Sep 2024
Decision date (initial)
2024-06-14
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Not applicable - Healthy volonteers

VersionLevelCodeTermSystem organ class
20.0 LLT 10014697 Endocrine disorder NOS 10014698

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Structure Therapeutics Inc.

Sponsor organisation
Structure Therapeutics Inc.
Address
601 Gateway Boulevard
City
South San Francisco
Postcode
94080-7006
Country
United States

Scientific contact point

Organisation
Structure Therapeutics Inc.
Contact name
Eric Meltzer

Public contact point

Organisation
Structure Therapeutics Inc.
Contact name
Eric Meltzer

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 8 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-06-24 2024-09-09 2024-06-24 2024-07-05

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-22 Netherlands Acceptable
2024-06-14
2024-06-14
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-17 Netherlands Acceptable
2024-07-02
2024-07-02
3 SUBSTANTIAL MODIFICATION SM-2 2024-09-10 Netherlands Acceptable
2024-10-01
2024-10-01